Aquestive Therapeutics Joins Leerink Partners I&I and Metabolism Forum on July 14

Aquestive Therapeutics' appearance at the Leerink Partners Therapeutics Forum: I&I and Metabolism on July 14, 2026 places its oral film delivery platform in front of an audience increasingly focused on differentiated drug delivery in immunology and metabolic disease. For contract manufacturing and regulatory leads tracking the CDMO landscape, the company's dual operating model warrants attention.

Warren, N.J.-based Aquestive operates simultaneously as a proprietary drug developer and a Contract Development and Manufacturing Organization (CDMO), manufacturing exclusively for licensees across six continents. Its Indiana-based production facilities underpin four commercialized products using the proprietary PharmFilm® oral film technology. That U.S.-based manufacturing footprint carries supply-chain and GMP compliance implications for any licensee evaluating domestic sourcing continuity under current regulatory expectations.

The forum participation coincides with active clinical-stage work on two pipeline assets. Anaphylm™ (dibutepinephrine), a sublingual film for severe allergic reactions including anaphylaxis, and AQST-108, a topical epinephrine prodrug gel targeting dermatological conditions such as alopecia areata, both draw from the company's AdrenaVerse™ platform, a library of more than 20 epinephrine prodrugs. For QA and regulatory affairs teams at potential licensee organizations, the breadth of that prodrug library signals a pipeline that could generate additional technology transfer and process validation workstreams.

Management will also host one-on-one investor meetings alongside the panel sessions, though the operational read for plant heads and QA directors centers less on capital markets positioning and more on what expanded licensee uptake of PharmFilm® would mean for manufacturing capacity allocation and batch release obligations at the Indiana site.

The July 14 forum date provides a near-term checkpoint for any organization monitoring Aquestive's CDMO pipeline activity and the regulatory trajectory of Anaphylm™ ahead of anticipated submission milestones.

Source: Aquestive Therapeutics, Inc. via GlobeNewswire, July 7, 2026.